State Street SPDR S&P Biotech ETF
427 hedge funds and large institutions have $4.36B invested in State Street SPDR S&P Biotech ETF in 2018 Q4 according to their latest regulatory filings, with 92 funds opening new positions, 113 increasing their positions, 149 reducing their positions, and 91 closing their positions.
8.22% more ownership
Funds ownership: 106.32% → 114.54% (+8.2%)
1% more first-time investments, than exits
New positions opened: 92 | Existing positions closed: 91
1% less funds holding
Funds holding: 432 → 427 (-5)
24% less capital invested
Capital invested by funds: $5.71B → $4.36B (-$1.35B)
24% less repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 149
30% less funds holding in top 10
Funds holding in top 10: 20 → 14 (-6)
46% less call options, than puts
Call options by funds: $1.01B | Put options by funds: $1.89B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$402M |
| 2 |
Citigroup
New York
|
+$185M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$51.4M |
| 4 |
Jane Street
New York
|
+$50M |
| 5 |
Morgan Stanley
New York
|
+$28.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$180M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$149M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$93.1M |
| 4 |
AssetMark Inc
Concord,
California
|
-$66.9M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$65.6M |
XBI Hedge Fund Activity: Q4 2018 in Review
427 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q4 2018, worth a combined $4.36B — down 24% from $5.71B a quarter earlier.
Buyers outnumbered sellers: 92 funds opened new XBI positions and 91 closed out — a net gain of 1 holder — while 113 added to existing stakes and 149 trimmed.
The largest buyer was UBS Group, adding an estimated $402M. The largest seller was Goldman Sachs, cutting an estimated $180M.
- 427 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q4 2018, down from 432 in Q3 2018.
- Funds reported $4.36B of State Street SPDR S&P Biotech ETF stock for Q4 2018, down 24% quarter-over-quarter.
- 92 funds opened new State Street SPDR S&P Biotech ETF positions in Q4 2018 and 91 closed out, a net change of +1 holder.
- The largest State Street SPDR S&P Biotech ETF buyer in Q4 2018 was UBS Group, an estimated $402M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q4 2018 was Goldman Sachs, an estimated $180M sold.
Based on aggregated 13F filings for Q4 2018.